SHZ · 000538.SZ
Yunnan Baiyao Group Co.,Ltd
CN¥53.29+CN¥0.36 (+0.68%)
Yunnan Baiyao Group Co.,Ltd’s quoted price sits in the upper half of its reported 52-week range, 8.44% below the high.
Loading market information…
SHZ · 000963.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:57 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Huadong Medicine Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 39.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Huadong Medicine Co., Ltd’s forward annual dividend is CN¥0.70 per share, paid semi-annual. The forward yield is 2.63% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Huadong Medicine Co., Ltd’s next earnings report is currently expected on Apr 22, 2027, with estimated earnings per share of CN¥0.45. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Huadong Medicine Co., Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in China, primarily focused on the creation, production, and distribution of a wide variety of medicinal products. Its extensive product catalog encompasses traditional Chinese patent medicines, immunosuppressive agents, endocrine treatments, digestive system remedies, cancer therapeutics, cardiovascular medications, and antibiotics. The company also supplies medical devices and offers solutions in the field of aesthetic medicine. Noteworthy product lines include gastrointestinal agents and Active Pharmaceutical Ingredients (APIs). Beyond its core pharmaceutical activities, Huadong Medicine is involved in the manufacturing and management of both traditional Chinese and Western raw medicines, prepared formulations, and health supplements. Its operations extend to the wholesale trade of Traditional Chinese Medicine (TCM) ingredients, prepared TCM decoction pieces, and various chemical preparations, complemented by warehousing and logistical services. A significant area of focus for the company is the research, development, manufacturing, and commercialization of aesthetic medicine products. Established in 1993, Huadong Medicine Co., Ltd maintains its corporate headquarters in Hangzhou, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | Aug 19, 2025 | CN¥0.51+1.92% vs estimate | CN¥10.94B+0.12% vs estimate |
|---|
| Q1 2025 | Apr 24, 2025 | CN¥0.520.0% vs estimate | CN¥10.74B-8.56% vs estimate |
|---|
| Q3 2024 | Dec 31, 2024 | CN¥0.54 | CN¥10.43B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥53.29+CN¥0.36 (+0.68%)
Yunnan Baiyao Group Co.,Ltd’s quoted price sits in the upper half of its reported 52-week range, 8.44% below the high.
CN¥25.16+CN¥0.25 (+1.0%)
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.91% below the high.
CN¥16.43+CN¥0.53 (+3.33%)
Zhejiang Huahai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 15.18% below the high.
CN¥23.67+CN¥0.04 (+0.17%)
Guangdong Zhongsheng Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.93% below the high.
CN¥19.00+CN¥0.10 (+0.53%)
Chengdu Kanghong Pharmaceutical Group Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 46.57% below the high.
CN¥22.28+CN¥0.20 (+0.91%)
China Resources Jiangzhong Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 19.94% below the high.
CN¥14.20-CN¥0.10 (-0.7%)
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd’s quoted price sits in the lower half of its reported 52-week range, 52.98% below the high.
CN¥73.80+CN¥0.75 (+1.03%)
Fujian Cosunter Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.47% below the high.
